Terms: = Bone cancer AND SPOP, TEF2, 8405, ENSG00000121067, O43791 AND Treatment
5 results:
1. Differences and Common Ground in
Farolfi A; Armstrong WR; Djaileb L; Gafita A; Hotta M; Allen-Auerbach M; Unterrainer LM; Fendler WP; Rettig M; Eiber M; Hofman MS; Hadaschik B; Herrmann K; Czernin J; Calais J; Benz MR
J Nucl Med; 2024 Mar; 65(3):438-445. PubMed ID: 38238041
[No Abstract] [Full Text] [Related]
2. Genomic Features of Lung-Recurrent Hormone-Sensitive Prostate cancer.
Fonseca NM; Van der Eecken K; Herberts C; Verbeke S; Ng SWS; Lumen N; Ritch E; Murtha AJ; Bernales CQ; Schönlau E; Moris L; Van Dorpe J; Annala M; Wyatt AW; Ost P
JCO Precis Oncol; 2022 Apr; 6():e2100543. PubMed ID: 35507889
[TBL] [Abstract] [Full Text] [Related]
3. Oncogenic Genomic Alterations, Clinical Phenotypes, and Outcomes in Metastatic Castration-Sensitive Prostate cancer.
Stopsack KH; Nandakumar S; Wibmer AG; Haywood S; Weg ES; Barnett ES; Kim CJ; Carbone EA; Vasselman SE; Nguyen B; Hullings MA; Scher HI; Morris MJ; Solit DB; Schultz N; Kantoff PW; Abida W
Clin Cancer Res; 2020 Jul; 26(13):3230-3238. PubMed ID: 32220891
[TBL] [Abstract] [Full Text] [Related]
4. The emerging role of spop protein in tumorigenesis and cancer therapy.
Song Y; Xu Y; Pan C; Yan L; Wang ZW; Zhu X
Mol Cancer; 2020 Jan; 19(1):2. PubMed ID: 31901237
[TBL] [Abstract] [Full Text] [Related]
5. LuCaP Prostate cancer Patient-Derived Xenografts Reflect the Molecular Heterogeneity of Advanced Disease an--d Serve as Models for Evaluating cancer Therapeutics.
Nguyen HM; Vessella RL; Morrissey C; Brown LG; Coleman IM; Higano CS; Mostaghel EA; Zhang X; True LD; Lam HM; Roudier M; Lange PH; Nelson PS; Corey E
Prostate; 2017 May; 77(6):654-671. PubMed ID: 28156002
[TBL] [Abstract] [Full Text] [Related]
